Publications 2008

  1. Nuesch R, Ananworanich J, Srasuebkul P, Chetchotisakd P Prasithsirikul W, Klinbuayam W, Mahanontharit A, Jupimai T, Ruxrungtham K, Hirschel B. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. AIDS. 2008 Jan 2;22(1):152-4.
  2. Ananworanich J, Jupimai T, Mekmullica J, Sosothikul D, Pancharoen C. Behavioral and Emotional Problems in Thai Children with HIV Infection Compared to Children with and without other Chronic Disease. J Int Assoc Physicians AIDS Care (Chic). 2008 Jan-Feb;7(1):52-3. doi: 10.1177/1545109707305173.
  3. Ananworanich J, Pumpradit W, Apateerapong W, Siangphoe U, Saenawat S, Phanuphak P, Hirschel B. Preference for CD4-guided versus continuous HARRT in Thailand. AIDS Care. 2008 Mar;20(3):327-30. doi: 10.1080/09540120701660304.
  4. Van der Lugt J, Autar RS, Ubolyam S, Garcia EF, Sankote J, Avihingsanon A, Chuenyam T, Cooper DA, Lange J, Phanuphak P, Wit F, Ruxrungtham K, Burger D; HIV-NAT 019 Study Team. Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naïve HIV-1-infected adults. J Antimicrob Chemother. 2008 May;61(5):1145-53. doi: 10.1093/jac/dkn050. Epub 2008 Feb 18.
  5. Cressey TR, Green H, Khoo S, Treluyer JM, Compagnucci A, Saidi Y, Lallemant M, Gibb DM, Burger DM; Paediatric European Network for Treatment of AIDS II Study Group. Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children. Clin Infect Dis. 2008 May 15;46(10):1601-8. doi: 10.1086/587657.
  6. Ananworanich J, Nuesch R, Cote HC, Kerr SJ, Hill A, Jupimai T, Laopraynak N, Saenawat S, Ruxrungtham K, Hirschel B. Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine—a Staccato trials substudy. J Antimicrob Chemother. 2008 Jun;61(6):1340-3. doi: 10.1093/jac/dkn097. Epub 2008 Mar 12.
  7. Kosalaraksa P, Bunupuradah T, Engchanui C, Boonrak P, Intasan J, Lumbianon P, Burger D, Ruxrungtham K, Schutz M, Ananworanich J; HIV-NAT 017 Study Team. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks. Pediatr Infect Dis J. 2008 Jul;27(7):623-8. doi: 10.1097/INF.0b013e31816b4539.
  8. Ananworanich J, Puthanakit T, Saphonn V, Cooper DA, Ruxrungtham K. Lessons from a multicentre paediatric HIV trial. Lancet. 2008 Aug 2;372(9636):356-7. doi: 10.1016/S0140-6736(08)61139-3.
  9. Mangclaviraj S, Kerr SJ, Chaithongwongwatthana S, Ananworanich J, Hirschel B, Emery S, Cooper DA, Chotnopparatpattara P, Ruxrungtham K, Phanuphak P. Nadir CD4 count and monthly income predict cervical squamous cell abnormalities in HIV-positive women in a resource-limited setting. Int J STD AIDS. 2008 Aug;19(8):529-32. doi: 10.1258/ijsa.2007.007222.
  10. Preiss S, Littlejohn M, Angus P, Thompson A, Desmond P, Lewin SR, Sasadeusz J, Matthews G, Dore GJ, Shaw T, Sozzi V, Yuen L, Lau G, Ayres A, Thio C, Avihingsanon A, Ruxrungtham K, Locarnini S, Revill PA. Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance. Hepatology. 2008 Sep;48(3):741-9. doi: 10.1002/hep.22386.
  11. Boom J, Kosters E, Duncombe C, Kerr S, Hirschel B, Ruxrungtham K, de Mast Q, Kosalaraksa P, Ubolyam S, Jupimai T, Ananworanich J; Staccato Study Group. Ferritin levels during structured treatment interruption of highly active antiretroviral therapy. HIV Med. 2007 Sep;8(6):388-95.
  12. Ananworanich J, Kosalaraksa P, Siangphoe U, Engchanil C, Pancharoen C, Lumbignon P, Intasan J, Apateerapong W, Chuenyam T, Ubolyam S, Bunupuradah T, Lange J, Cooper DA, Phanuphak P; the HIV-NAT 010 Study Team. A feasibility study of immediate versus deferred antiretroviral therapy in children with HIV infection. AIDS Res Ther. 2008 Oct 28;5:24. doi: 10.1186/1742-6405-5-24.
  13. Srisawat N, Avihingsanon A, Praditpornsilpa K, Jiamjarasrangsi W, Eiam-Ong S, Avihingsanon Y. A prevalence of posttransplantation cancers compared with cancers in people with human immunodeficiency virus/acquired immunodeficiency syndrome after highly active antiretroviral therapy. Transplant Proc. 2008 Oct;40(8):2677-9. doi: 10.1016/j.transproceed.2008.07.061.
  14. Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R, Petcharapirat P, Marks P, Sasadeusz J, Cooper DA, Bowden S, Locarnini S, Ruxrungtham K, Dore GJ. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individual in Thailand. Hepatology. 2008 Oct;48(4):1062-9. doi: 10.1002/hep.22462.
  15. Ananworanich J, Phanuphak N, de Souza M, Paris R, Arroya M, Trichavaroj R, Sirivichayakul S,Shikuma C, Phanuphak P, Kim JH; South East Asia Research Collaboration with Hawaii 004 Protocol Team. Incidence and characterization of acute HIV-1 infection in a high-risk Thai population. J Acquir Immune Defic Syndr. 2008 Oct 1;49(2):151-5. doi: 10.1097/QAI.0b013e318183a96d.
  16. Van der Lugt J, Colbers A, Burger D. Clinical pharmacology of HIV protease inhibitors in pregnancy. Curr Opin HIV AIDS. 2008 Nov;3(6):620-6. doi: 10.1097/COH.0b013e3283136cc5.
  17. Ruxrungtham K, Pedro RJ, Latiff GH, Conradie F, Domingo P, Lupo S, Pumpradit W, Vingerhoets JH, Peeters M, Peeters I, Kakuda TN, De Smedt G, Woodfall B; TMC125-C227 study group. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. HIV Med. 2008 Nov;9(10):883-96. doi: 10.1111/j.1468-1293.2008.00644.x. Epub 2008 Sep 14.
  18. Ananworanich J, Gayet-Ageron A, Ruxrungtham K, Chetchotisakd P, Prasithsirikul W, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, LeBraz M, Jumpimai T, Ubolyam S, Schutz M, Hirschel B; Staccato Thailand Study Group. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. Antivir Ther. 2008;13(3):375-80.
  19. Avihingsanon A, Manosuthi W, Kantipong P, Chuchotaworn C, Moolphate S, Sakornjun W, Gorowara M, Yamada N, Yanai H, Mitarai S, Ishikawa N, Cooper DA, Phanuphak P, Burger D, Ruxrungtham K. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin. Antivir Ther. 2008;13(4):529-36.
  20. Langford S, Gayet-Ageron A, Duncombe C, Jupimai T, Mahanontharit A, Kiertiburanakul S, Munsakul W, Ruxrungtham K, Hirschel B, Ananworanich J. Supersensitive Viral Load Assay in Predicting CD4-Guided Treatment Failure. Open Virol J. 2008;2:69-73. doi: 10.2174/1874357900802010069. Epub 2008 Oct 16.